Arbutus Biopharma Corporation Common Stock ABUS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T09:46:30.811Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-04T09:04:54.223484884Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T09:44:09.923127+00:00
Arbutus Biopharma Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 3.55 | 67.2% | 10.9% | |||
| 30Δ | 4.44 | 98.8% | 18.2% | 3.61 | 64.6% | 9.7% |
| 35Δ | 4.33 | 99.1% | 16.1% | 3.68 | 62.0% | 8.5% |
| 40Δ | 4.21 | 99.5% | 13.9% | |||
| 45Δ | 4.09 | 99.8% | 11.8% | |||
| 50Δ | 3.98 | 99.3% | 9.8% | |||
| 55Δ | 3.88 | 96.3% | 8.5% | |||
| 60Δ | 3.79 | 93.3% | 7.1% | |||
| 65Δ | 3.69 | 90.2% | 5.8% | |||
| 70Δ | 3.60 | 87.2% | 4.5% | |||
| 75Δ | 3.50 | 84.2% | 3.1% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.55
- IV
- 67.2%
- B/E move
- 10.9%
30Δ
- Pseudo strike
- 4.44
- IV
- 98.8%
- B/E move
- 18.2%
- Pseudo strike
- 3.61
- IV
- 64.6%
- B/E move
- 9.7%
35Δ
- Pseudo strike
- 4.33
- IV
- 99.1%
- B/E move
- 16.1%
- Pseudo strike
- 3.68
- IV
- 62.0%
- B/E move
- 8.5%
40Δ
- Pseudo strike
- 4.21
- IV
- 99.5%
- B/E move
- 13.9%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 4.09
- IV
- 99.8%
- B/E move
- 11.8%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 3.98
- IV
- 99.3%
- B/E move
- 9.8%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 3.88
- IV
- 96.3%
- B/E move
- 8.5%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.79
- IV
- 93.3%
- B/E move
- 7.1%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 3.69
- IV
- 90.2%
- B/E move
- 5.8%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 3.60
- IV
- 87.2%
- B/E move
- 4.5%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 3.50
- IV
- 84.2%
- B/E move
- 3.1%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 100.50% | |
| 77.72% | |
| 66.29% | |
| 159.76% | |
| 115.60% | |
| 143.09% | |
| 98.27% | |
| 131.48% | |
| 128.65% | |
| 159.93% | |
| 144.71% | |
| 163.05% | |
| 180.24% | |
| 194.02% | |
| 175.83% | |
| 231.11% | |
| 196.36% | |
| 170.73% | |
| 115.65% | |
| 96.75% | |
| 97.15% | |
| 134.34% | |
| 91.39% | |
| 113.20% | |
| 149.02% | |
| 215.71% | |
| 163.52% | |
| 195.23% | |
| 367.14% | |
| 174.66% | |
| 125.49% | |
| 217.46% | |
| 227.48% | |
| 177.19% | |
| 150.27% | |
| 208.31% | |
| 212.73% | |
| 141.51% | |
| 208.58% | |
| 128.16% | |
| 251.83% |
Biotechnology
ABVX
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in…
More →ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central…
More →ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston,…
More →ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and…
More →ACIU
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative…
More →ACOG
Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on…
More →